Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis

Clinical and Vaccine Immunology

Volumn 18, Issue 6, 2011, Pages 931-939

  Loza, Matthew J ^a   Brodmerkel, Carrie ^a   Du Bois, Roland M ^b   Judson, Marc A ^c   Costabel, Ulrich ^d   Drent, Marjolein ^e   Kavuru, Mani ^f   Flavin, Susan ^a   Lo, Kim Hung ^a   Barnathan, Elliot S ^a   Baughman, Robert P ^g  

^a CENTOCOR INC   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PLACEBO; RANTES; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR II; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MALE; MIDDLE AGED; PLACEBOS; SARCOIDOSIS, PULMONARY; SERUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957987361     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00337-10     Document Type: Article

References (24)

1. Anonymous. 1999. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 160:736-755.
2. Baughman, R. P., et al. 2006. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 174:795-802.
3. Baughman, R. P., E. E. Lower, and M. Drent. 2008. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc. Diffuse Lung Dis. 25:76-89.
4. Boots, A. W., et al. 2009. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir. Med. 103:364-372.
5. Capelli, A., A. Di Stefano, M. Lusuardi, I. Gnemmi, and C. F. Donner. 2002. Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 165:236-241.
6. Car, B. D., et al. 1994. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 149:655-659.
7. Dabney, A., and J. Storey. 2008. Q-value. http://genomics.princeton.edu/ storeylab/qvalue/.
8. Drent, M., et al. 1999. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur. Respir. J. 13:1338-1344. (Pubitemid 29357150)
9. Hashimoto, S., et al. 1998. Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1alpha (MIP-1alpha) levels with disease activity and clinical course of sarcoidosis. Clin. Exp. Immunol. 111:604-610.
10. Iida, K., et al. 1997. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis. Thorax 52:431-437. (Pubitemid 27278140)
11. Iyonaga, K., et al. 1998. Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 15:165-172.
12. Judson, M. A., et al. 2008. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur. Respir. J. 31:1189-1196.
13. Koczan, D., et al. 2008. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res. Ther. 10:R50.
14. Kodama, N., et al. 1998. Expression of RANTES by bronchoalveolar lavage cells in nonsmoking patients with interstitial lung diseases. Am. J. Respir. Cell Mol. Biol. 18:526-531.
15. Newman, L. S., et al. 2004. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am. J. Respir. Crit. Care Med. 170:1324-1330.
16. Petrek, M., V. Kolek, J. Szotkowska, and R. M. du Bois. 2002. CC and C chemokine expression in pulmonary sarcoidosis. Eur. Respir. J. 20:1206-1212.
17. Petrek, M., et al. 1997. The source and role of RANTES in interstitial lung disease. Eur. Respir. J. 10:1207-1216.
18. Rules Based Medicine. 2008. Human MAP version 1.6. http://www. rulesbasedmedicine.com/products-services/humanmap-services/humanmap/.
19. Shigehara, K., et al. 2001. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol. 166:642-649. (Pubitemid 32038488)
20. Storey, J. 2002. A direct approach to false discovery rates. J. R. Stat. Soc. B 64:479-498.
21. Suga, M., et al. 1999. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur. Respir. J. 14:376-382.
22. Sugiyama, K., et al. 2006. Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 11:708-714. (Pubitemid 44581434)
23. Vasakova, M., et al. 2009. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand. J. Immunol. 69:268-274.
24. Zissel, G., A. Prasse, and J. Muller-Quernheim. 2007. Sarcoidosis-immunopathogenetic concepts. Semin. Respir. Crit. Care Med. 28:3-14.